ArticleAnimal models and experimental medicine2025
Long-term immunosuppression of rabbits through oral tacrolimus administration.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Noninvasive electrodiagnostic and motor function assessment of the common fibular nerve regeneration in the rabbit hindlimb.Animal models and experimental medicine · 2025Article
- Long-term immunosuppression of rabbits through oral tacrolimus administration.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe absence of well-established immunosuppressed rabbit models poses a significant hurdle in xenograft experiments. Tacrolimus has been identified as a highly promising immunosuppressive agent for rabbits. However, determining the optimal dosage and route of administration to minimize toxicity while maintaining efficacy remains challenging.
methodsIn this study, we investigated the effect of orally administered tacrolimus in rabbits, with an aim to achieve a whole blood target trough level of 3-10 ng/mL, and looked at signs of tissue rejection after the transplantation of a human nerve conduit to repair a severed fibular nerve. An oral dosage range of 0.25-1.5 mg/kg/d was studied for up to 1 year in 63 New Zealand rabbits.
resultsWe demonstrated the feasibility of long-term grafting in rabbits while maintaining safe immunosuppression, with side effects mainly limited to diarrhea. Customizing the administered dose proved crucial for graft efficacy and low toxicity, which translated into 100% individual survival. We suggest an oral tacrolimus dose of 1.0-1.5 mg/kg depending on individual heterogeneity and recommend to implement a close therapeutic drug monitoring in the rabbits to maintain a whole blood tacrolimus trough level within the range of 5-12 ng/mL, as levels below 5 ng/mL showed signs of inflammation in the graft.
conclusionThe oral administration of tacrolimus enabled efficient immunosuppression of rabbits over a 1-year period without significant side effects or loss of animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.